[go: up one dir, main page]

GR1000989B - Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας. - Google Patents

Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.

Info

Publication number
GR1000989B
GR1000989B GR910100192A GR910100192A GR1000989B GR 1000989 B GR1000989 B GR 1000989B GR 910100192 A GR910100192 A GR 910100192A GR 910100192 A GR910100192 A GR 910100192A GR 1000989 B GR1000989 B GR 1000989B
Authority
GR
Greece
Prior art keywords
treatment
ormonic
ansororopia
hospitality
estrogen
Prior art date
Application number
GR910100192A
Other languages
English (en)
Other versions
GR910100192A (en
Inventor
G Grodberg Marcus
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of GR910100192A publication Critical patent/GR910100192A/el
Publication of GR1000989B publication Critical patent/GR1000989B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ενα φάρμακο για παροχή ιόντος φθορίου για την πρόληψη και θεραπεία ασθένειας απώλειας οστού, μαζί με μία ουσία που περιέχει οιστρογόνο όχι μόνο για θεραπεία ορμονικής ανισορροπίας αλλά και για να λαμβάνεται πιο πλεονεκτική χρήση ιόντος φθορίου στο σώμα. Η δοσολογία είναι ένας τροχίσκος, δισκίο ή κάψουλα, που περιέχει από 20 έως 100 χιλιοστογραμμάρια μονοφθοροφωσφορικού και περαιτέρω περιλαμβάνει μία ουσία που περιέχει οιστρογόνο και ένα μηχανισμό βραδείας απελευθέρωσης για ελεγχόμενη απελευθέρωση του ιόντος φθορίου και του οιστρογόνου, σε περίοδο από τέσσερις έως οκτώ ώρες μετά την κατάποση. Μέχρι δέκα τοις εκατό φθοριούχου νατρίου ή/και ασβεστίου μπορεί να προστίθεται. ω
GR910100192A 1990-05-04 1991-05-03 Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας. GR1000989B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/519,088 US5013728A (en) 1990-05-04 1990-05-04 Composition for treating osteoporosis and hormonal imbalance

Publications (2)

Publication Number Publication Date
GR910100192A GR910100192A (en) 1992-07-30
GR1000989B true GR1000989B (el) 1993-03-31

Family

ID=24066774

Family Applications (1)

Application Number Title Priority Date Filing Date
GR910100192A GR1000989B (el) 1990-05-04 1991-05-03 Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.

Country Status (12)

Country Link
US (1) US5013728A (el)
EP (1) EP0455503A1 (el)
JP (1) JPH04225921A (el)
AU (1) AU647111B2 (el)
BR (1) BR9101787A (el)
CA (1) CA2041799A1 (el)
FI (1) FI912160L (el)
GR (1) GR1000989B (el)
IE (1) IE911514A1 (el)
MX (1) MX166220B (el)
PT (1) PT97543A (el)
ZA (1) ZA913184B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5153005A (en) * 1990-12-11 1992-10-06 Colgate-Palmolive Company Composition and method for preventing fluorosis
DE59209889D1 (de) * 1991-09-13 2001-03-01 David J Baylink Knochenwachstumsfördernde zusammensetzung
DK0600079T3 (da) * 1992-06-22 2002-04-15 Bone Care Int Inc Oral 1alpha-hydroxyprævitamin D
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
ES2173911T3 (es) * 1992-12-29 2002-11-01 Michael F Holick Uso de glicosidos en vitamina d para el tratamiento o prevencion de la osteoporosis.
WO2000067708A2 (en) * 1999-05-07 2000-11-16 Board Of Regents, The University Of Texas System Oral steroidal hormone compositions and methods of use
ES2192136B1 (es) * 2002-01-04 2005-03-16 Italfarmaco, S.A. Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
US7138394B2 (en) * 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287219A (en) * 1963-08-05 1966-11-22 Charles J Nemanick Method of healing bone fractures
DE2630326C2 (de) * 1976-07-06 1983-07-21 "Gebro" G. Broschek Kg, Chemisch-Pharmazeutische Fabrik, 6391 Fieberbrunn, Tirol Präparat zur Behandlung der Osteoporose und seine Herstellung
US4185108A (en) * 1977-05-10 1980-01-22 Westwood Pharmaceuticals Inc. Antiosteoporotic agents
US4101668A (en) * 1977-05-10 1978-07-18 Bristol-Myers Company Antiosteoporotic agents
DK261278A (da) * 1977-06-13 1979-12-15 Merck & Co Inc Fremgangsmaade til fremstilling af 24-dehydrovitamin d-3-derivater
US4220552A (en) * 1978-06-05 1980-09-02 The United States Of America As Represented By The Department Of Health, Education & Welfare Method of producing delayed release of sodium fluoride
DE2922671C2 (de) * 1979-06-02 1982-08-19 Battelle-Institut E.V., 6000 Frankfurt Zahnpflege- und Zahnreinigungsmittel
AU532512B2 (en) * 1979-09-07 1983-10-06 Upjohn and Horton Anti-allergenic compounds for bone mineral resorption
FR2542199B1 (fr) * 1983-03-11 1986-01-10 Rizhskij Med Inst Medicament pour le traitement de la carie dentaire
US4726952A (en) * 1983-08-11 1988-02-23 Mission Pharmacal Slow-release sodium fluoride tablet, method of making, and method of treatment of osteoporosis
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4859467A (en) * 1986-09-25 1989-08-22 Colgate-Palmotive Company Sustained release fluoride composition
US4861590A (en) * 1986-09-25 1989-08-29 Colgate-Palmolive Company Sustained release fluoride and calcium composition
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
EP0322020A1 (en) * 1987-12-22 1989-06-28 Akzo N.V. Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
AU3435989A (en) * 1988-03-25 1989-10-16 Akzo N.V. Pharmaceutical preparation containing a fluoride salt

Also Published As

Publication number Publication date
BR9101787A (pt) 1991-12-17
GR910100192A (en) 1992-07-30
US5013728A (en) 1991-05-07
JPH04225921A (ja) 1992-08-14
FI912160A7 (fi) 1991-11-05
MX166220B (es) 1992-12-23
PT97543A (pt) 1992-01-31
AU647111B2 (en) 1994-03-17
EP0455503A1 (en) 1991-11-06
IE911514A1 (en) 1991-11-06
FI912160L (fi) 1991-11-05
ZA913184B (en) 1992-12-30
FI912160A0 (fi) 1991-05-03
CA2041799A1 (en) 1991-11-05
AU7591491A (en) 1991-11-07

Similar Documents

Publication Publication Date Title
YU135980A (en) Process for the manufacture of pharmaceutical formulations in the form of a polyacrylate film
ES509647A0 (es) Procedimiento para preparar una polilactida.
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
ATE189400T1 (de) Knochenwachstumsfördernde zusammensetzung
NZ228130A (en) Therapeutic composition comprising fenofibrate and a solid surfactant which has been co-micronised; preparatory process
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
MY107088A (en) Plaster used as therapeutic system for the administration of active substances to the skin, which exhibits a graduated active substance release,process for the production of the plaster and use thereof
GR1000989B (el) Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.
ES2033021T3 (es) Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer.
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
ATE340561T1 (de) Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen
ES2037808T3 (es) Procedimiento para la obtencion de medicamentos para la profilaxis y terapia de enfermedades producidas por retrovirus.
FI971742A7 (fi) Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskauden ehkäisyyn naisilla
SE8703632D0 (sv) Sustained release fluoride composition
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
ES2097952T3 (es) Comprimidos de liberacion programada que contienen naproxeno.
IT1151953B (it) Composizione farmaceutica per la cura di affezioni della cavita' orale
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
MX9307479A (es) Uso de ciertos derivados de acido metanobisfosfonico en la curacion de fracturas.